A detailed history of Balentine LLC transactions in Amgen Inc stock. As of the latest transaction made, Balentine LLC holds 830 shares of AMGN stock, worth $218,439. This represents 0.01% of its overall portfolio holdings.

Number of Shares
830
Previous 827 0.36%
Holding current value
$218,439
Previous $258,000 3.49%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

BUY
$309.38 - $337.38 $928 - $1,012
3 Added 0.36%
830 $267,000
Q2 2024

Aug 07, 2024

SELL
$262.75 - $319.31 $1.98 Million - $2.4 Million
-7,525 Reduced 90.1%
827 $258,000
Q1 2024

May 15, 2024

BUY
$268.87 - $324.56 $149,760 - $180,779
557 Added 7.15%
8,352 $2.37 Million
Q4 2023

Feb 09, 2024

BUY
$255.7 - $288.46 $440,571 - $497,016
1,723 Added 28.38%
7,795 $2.25 Million
Q3 2023

Nov 13, 2023

BUY
$218.65 - $271.46 $305,672 - $379,501
1,398 Added 29.91%
6,072 $1.63 Million
Q2 2023

Aug 14, 2023

SELL
$214.27 - $253.37 $67,066 - $79,304
-313 Reduced 6.28%
4,674 $1.04 Million
Q1 2023

May 11, 2023

SELL
$225.79 - $275.2 $419,743 - $511,596
-1,859 Reduced 27.15%
4,987 $1.21 Million
Q4 2022

Jan 31, 2023

BUY
$229.03 - $291.01 $22,444 - $28,518
98 Added 1.45%
6,846 $1.8 Million
Q3 2022

Oct 26, 2022

BUY
$224.46 - $253.15 $101,904 - $114,930
454 Added 7.21%
6,748 $1.52 Million
Q2 2022

Oct 26, 2022

BUY
$230.71 - $256.74 $437,656 - $487,035
1,897 Added 43.14%
6,294 $1.53 Million
Q2 2022

Aug 15, 2022

BUY
$230.71 - $256.74 $1.45 Million - $1.62 Million
6,294 New
6,294 $1.53 Million
Q1 2022

Oct 26, 2022

SELL
$219.27 - $242.57 $415,955 - $460,155
-1,897 Reduced 30.14%
4,397 $1.06 Million
Q4 2021

Oct 26, 2022

SELL
$198.88 - $227.6 $741,026 - $848,037
-3,726 Reduced 59.2%
2,568 $578,000
Q4 2021

Feb 02, 2022

SELL
$198.88 - $227.6 $262,919 - $300,887
-1,322 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$212.27 - $248.7 $3,820 - $4,476
-18 Reduced 1.34%
1,322 $281,000
Q2 2021

Aug 16, 2021

SELL
$233.58 - $259.14 $98,337 - $109,097
-421 Reduced 23.91%
1,340 $327,000
Q1 2021

May 10, 2021

BUY
$221.91 - $258.6 $57,696 - $67,236
260 Added 17.32%
1,761 $438,000
Q4 2020

Feb 08, 2021

BUY
$216.38 - $257.67 $6,275 - $7,472
29 Added 1.97%
1,501 $345,000
Q3 2020

Nov 02, 2020

BUY
$234.65 - $260.95 $35,666 - $39,664
152 Added 11.52%
1,472 $374,000
Q2 2020

Aug 14, 2020

BUY
$197.81 - $242.74 $147,368 - $180,841
745 Added 129.57%
1,320 $311,000
Q1 2020

May 18, 2020

SELL
$182.24 - $241.7 $80,003 - $106,106
-439 Reduced 43.29%
575 $117,000
Q4 2019

Sep 02, 2020

BUY
$189.21 - $243.2 $157,611 - $202,585
833 Added 460.22%
1,014 $244,000
Q3 2019

Nov 15, 2019

BUY
$174.11 - $208.62 $8,357 - $10,013
48 Added 36.09%
181 $35,000
Q2 2019

Aug 14, 2019

BUY
$166.7 - $195.41 $11,168 - $13,092
67 Added 101.52%
133 $25,000
Q1 2019

May 16, 2019

SELL
$180.87 - $203.88 $9,586 - $10,805
-53 Reduced 44.54%
66 $13,000
Q3 2018

Nov 14, 2018

BUY
$185.29 - $208.89 $22,049 - $24,857
119 New
119 $25,000
Q1 2018

May 16, 2018

SELL
$169.43 - $198.0 $203,654 - $237,996
-1,202 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$168.79 - $188.59 $19,579 - $21,876
116 Added 10.68%
1,202 $209,000
Q3 2017

Nov 15, 2017

BUY
$167.29 - $191.0 $181,676 - $207,426
1,086
1,086 $202,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $141B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Balentine LLC Portfolio

Follow Balentine LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balentine LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balentine LLC with notifications on news.